Drugs / hepatitis B virus immune globulin
hepatitis B virus immune globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00895713 | Nov 2004 → Jun 2005 | chronic hepatitis B virus infection | Grifols, S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hepatitis B virus immune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00895713 ↗ |
| Modality | Protein / enzyme biologic | “a new specific hepatitis B immune globulin” NCT00895713 ↗ |
| Route | Intramuscular | “Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months” NCT00895713 ↗ |